Why Did PFSA Stock Surge 150% Today?

• Profusa will gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools.
• Profusa will pay BioInsights about $30 million in equity.
• BioInsights will receive a 3% royalty on future net revenue.

Shares of Profusa, Inc. (PFSA) surged 150% on Monday after the company announced plans to enter the molecular diagnostics space through a proposed acquisition of the PanOmics diagnostic platform from BioInsights.

Under the agreement, Profusa would gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools, from BioInsights, for about $30 million. The consideration is payable in equity, the firm stated.

BioInsights will receive a 3% royalty on future net revenue. The move is expected to add to Profusa’s real-time biochemistry monitoring technology.

Mayo Clinic Collaboration

With access to clinical samples, a validation plan, and a partnership with the Mayo Clinic, the company believes it is well positioned to speed up development, increase clinical use, and create strong near-term growth.

“The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring. The entry into pancreatic cancer is instrumental in our establishing a platform capable of supporting multiple indications and long-term growth,” said Ben Hwang, Profusa Chairman and CEO. 

Potential For Recurring Revenue 

Combining the PanOmics platform with its biosensing technology could enable multi-indication diagnostics, real-time monitoring, and data-driven clinical tools, Profusa said. The company aims to expand into high-growth markets and build a scalable, recurring-revenue platform. 

It will also support its pancreatic cancer treatment efforts, using the Lumee oxygen system to improve monitoring during complex surgeries, a market with significant annual revenue potential.

How Did Retail Traders React?

Retail sentiment on Stocktwits for PFSA remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.

One user expects the stock to be a multi-day runner following the news.

Another user expects the stock to rise to $1.94 due to strong volumes. It is currently at $1.85.

Year-to-date, the stock has shed around 65%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.